Exact Mass: 529.294

Glycochenodeoxycholate 7-sulfate

C26H43NO8S (529.2709)

Glycochenodeoxycholate 7-sulfate is a bile acid derivative that plays several important roles in biology. Its primary functions include: Bile Acid Conjugation: It is a component of bile, which is synthesized in the liver and plays a crucial role in the digestion and absorption of dietary fats. The glyco moiety (sugar component) and sulfate group enhance its solubility and stability, facilitating its role in bile formation. Lipid Solubilization: In the small intestine, Glycochenodeoxycholate 7-sulfate aids in the emulsification of dietary fats. This process breaks down large fat droplets into smaller ones, increasing the surface area for action by lipase, an enzyme that breaks down triglycerides into absorbable fatty acids and monoglycerides. Cholesterol Homeostasis: Bile acids, including Glycochenodeoxycholate 7-sulfate, are involved in the regulation of cholesterol homeostasis. They facilitate the excretion of cholesterol from the body and also play a role in the enterohepatic circulation of bile acids, which recycles bile acids and helps maintain their levels. Hormonal Regulation: Bile acids, including conjugated forms like Glycochenodeoxycholate 7-sulfate, act as signaling molecules that interact with various nuclear and membrane receptors, influencing processes such as glucose and lipid metabolism, inflammation, and energy homeostasis. Detoxification: The sulfate group in Glycochenodeoxycholate 7-sulfate is involved in the detoxification of certain xenobiotics (foreign substances), aiding in their elimination from the body.

N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]-Glycine

C26H43NO8S (529.2709)

N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]-Glycine is an acyl glycine and a bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment. In hepatocytes, both primary and secondary bile acids undergo amino acid conjugation at the C-24 carboxylic acid on the side chain, and almost all bile acids in the bile duct therefore exist in a glycine conjugated form (PMID: 16949895). Technically this compound is a sulfate conjugate of glycoursodeoxycholic acid.

Glycochenodeoxycholate-3-sulfate

C26H43NO8S (529.2709)

Glycochenodeoxycholate-3-sulfate is a bile salt formed in the liver from chenodeoxycholate and glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is a cholagogue and choleretic. [HMDB] Glycochenodeoxycholate-3-sulfate is a bile salt formed in the liver from chenodeoxycholate and glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is a cholagogue and choleretic. D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids

LysoPE(0:0/22:4(7Z,10Z,13Z,16Z))

C27H48NO7P (529.3168)

LysoPE(0:0/22:4(7Z,10Z,13Z,16Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/22:4(7Z,10Z,13Z,16Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.

LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0)

C27H48NO7P (529.3168)

LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.

(5Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine

C30H43NO7 (529.3039)

(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

Gcdcs

C26H43NO8S (529.2709)

Haloperidol decanoate

C31H41ClFNO3 (529.2759)

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist

N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]-Glycine

C26H43NO8S (529.2709)

Homodeoxyharringtonine

C29H39NO8 (529.2676)

9-Deoxyglanduline 13-acetate

C29H39NO8 (529.2676)

14-O-Acetyl-9-deoxyglanduline

C29H39NO8 (529.2676)

Lucidamine B

C33H39NO5 (529.2828)

2-{(4S,5S,5aS,9aS)-4-Methoxy-6,6,9a-trimethyl-5-[(2E,4E,6E)-2,4,6-octatrienoyloxy]-1-oxo-1,3,4,5,5a,6,7,8,9,9a-decahydro-2H-benzo[E]isoindol-2-yl}pentanedioic acid

C29H39NO8 (529.2676)

Phosphatidylethanolamine lyso 22:4

C27H48NO7P (529.3168)

C30H43NO7

C30H43NO7 (529.3039)

(Z)-6-[(2R,5R,8R,11R,12S)-8-(4-hydroxybenzyl)-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-11-yl]hex-4-enamide|azumamide B

C27H39N5O6 (529.29)

Sativanine C

C27H39N5O6 (529.29)

Rostratin|Rostratine

C29H39NO8 (529.2676)

4-O-(alpha-L-arabinopyranosyl) nervogenic acid lindelofidine ester|nervosine I

C30H43NO7 (529.3039)

leopolic acid A

C29H43N3O6 (529.3152)

stachybotrin E

C29H39NO8 (529.2676)

stachybotrin F

C29H39NO8 (529.2676)

Leu Gly Asp Val Ile

C24H43N5O8 (529.3111)

Arg Leu Val Glu

C23H43N7O7 (529.3224)

Leu Arg Val Glu

C23H43N7O7 (529.3224)

Ala Lys Gly Arg Val

C22H43N9O6 (529.3336)

Ile Asp Leu Arg

C23H43N7O7 (529.3224)

Leu Ile Asp Arg

C23H43N7O7 (529.3224)

Leu Thr Pro Asp Ala

C23H39N5O9 (529.2748)

Leu Asn Ala Ala Lys

C23H43N7O7 (529.3224)

Ala Ala Gln Asn Leu

C22H39N7O8 (529.286)

C29H39NO8_2-{(4S,5S,5aS,9aS)-4-Methoxy-6,6,9a-trimethyl-5-[(2E,4E,6E)-2,4,6-octatrienoyloxy]-1-oxo-1,3,4,5,5a,6,7,8,9,9a-decahydro-2H-benzo[e]isoindol-2-yl}pentanedioic acid

C29H39NO8 (529.2676)

C29H39NO8_2-(4-Hydroxy-6-methoxy-1-oxo-5-{[(2E,6Z)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]oxy}-1,3-dihydro-2H-isoindol-2-yl)pentanedioic acid

C29H39NO8 (529.2676)

2-[(4S,5S,5aS,9aS)-4-methoxy-6,6,9a-trimethyl-5-[(2E,4E,6E)-octa-2,4,6-trienoyl]oxy-1-oxo-4,5,5a,7,8,9-hexahydro-3H-benzo[e]isoindol-2-yl]pentanedioic acid

C29H39NO8 (529.2676)

Glyco 3a-sulfate-7a-OH-5b-cholanic acid

C26H43NO8S (529.2709)

BA-145-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-145-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-145-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-145-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-145-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.

Glyco 3a-sulfate-7b-OH-5b-cholanic acid

C26H43NO8S (529.2709)

BA-146-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-146-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-146-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-146-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-146-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.

N-[(3a,5b,12a)-12-Hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]glycine

C26H43NO8S (529.2709)

BA-147-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-147-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-147-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-147-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-147-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.

Ala Phe His Arg

C24H35N9O5 (529.2761)

Ala Phe Arg His

C24H35N9O5 (529.2761)

Ala His Phe Arg

C24H35N9O5 (529.2761)

Ala His Arg Phe

C24H35N9O5 (529.2761)

Ala Gln Arg Arg

C20H39N11O6 (529.3085)

Ala Arg Phe His

C24H35N9O5 (529.2761)

Ala Arg His Phe

C24H35N9O5 (529.2761)

Ala Arg Gln Arg

C20H39N11O6 (529.3085)

Ala Arg Arg Gln

C20H39N11O6 (529.3085)

Glu Ile Ile Arg

C23H43N7O7 (529.3224)

Glu Ile Leu Arg

C23H43N7O7 (529.3224)

Glu Ile Arg Ile

C23H43N7O7 (529.3224)

Glu Ile Arg Leu

C23H43N7O7 (529.3224)

Glu Leu Ile Arg

C23H43N7O7 (529.3224)

Glu Leu Leu Arg

C23H43N7O7 (529.3224)

Glu Leu Arg Ile

C23H43N7O7 (529.3224)

Glu Leu Arg Leu

C23H43N7O7 (529.3224)

Glu Arg Ile Ile

C23H43N7O7 (529.3224)

Glu Arg Ile Leu

C23H43N7O7 (529.3224)

Glu Arg Leu Ile

C23H43N7O7 (529.3224)

Glu Arg Leu Leu

C23H43N7O7 (529.3224)

Phe Ala His Arg

C24H35N9O5 (529.2761)

Phe Ala Arg His

C24H35N9O5 (529.2761)

Phe His Ala Arg

C24H35N9O5 (529.2761)

Phe His Ile Asn

C25H35N7O6 (529.2649)

Phe His Lys Val

C26H39N7O5 (529.3013)

Phe His Leu Asn

C25H35N7O6 (529.2649)

Phe His Asn Ile

C25H35N7O6 (529.2649)

Phe His Asn Leu

C25H35N7O6 (529.2649)

Phe His Gln Val

C25H35N7O6 (529.2649)

Phe His Arg Ala

C24H35N9O5 (529.2761)

Phe His Val Lys

C26H39N7O5 (529.3013)

Phe His Val Gln

C25H35N7O6 (529.2649)

Phe Ile His Asn

C25H35N7O6 (529.2649)

Phe Ile Asn His

C25H35N7O6 (529.2649)

Phe Lys His Val

C26H39N7O5 (529.3013)

Phe Lys Val His

C26H39N7O5 (529.3013)

Phe Leu His Asn

C25H35N7O6 (529.2649)

Phe Leu Asn His

C25H35N7O6 (529.2649)

Phe Asn His Ile

C25H35N7O6 (529.2649)

Phe Asn His Leu

C25H35N7O6 (529.2649)

Phe Asn Ile His

C25H35N7O6 (529.2649)

Phe Asn Leu His

C25H35N7O6 (529.2649)

Phe Gln His Val

C25H35N7O6 (529.2649)

Phe Gln Val His

C25H35N7O6 (529.2649)

Phe Arg Ala His

C24H35N9O5 (529.2761)

Phe Arg His Ala

C24H35N9O5 (529.2761)

Phe Val His Lys

C26H39N7O5 (529.3013)

Phe Val His Gln

C25H35N7O6 (529.2649)

Phe Val Lys His

C26H39N7O5 (529.3013)

Phe Val Gln His

C25H35N7O6 (529.2649)

His Ala Phe Arg

C24H35N9O5 (529.2761)

His Ala Arg Phe

C24H35N9O5 (529.2761)

His Phe Ala Arg

C24H35N9O5 (529.2761)

His Phe Ile Asn

C25H35N7O6 (529.2649)

His Phe Lys Val

C26H39N7O5 (529.3013)

His Phe Leu Asn

C25H35N7O6 (529.2649)

His Phe Asn Ile

C25H35N7O6 (529.2649)

His Phe Asn Leu

C25H35N7O6 (529.2649)

His Phe Gln Val

C25H35N7O6 (529.2649)

His Phe Arg Ala

C24H35N9O5 (529.2761)

His Phe Val Lys

C26H39N7O5 (529.3013)

His Phe Val Gln

C25H35N7O6 (529.2649)

His Ile Phe Asn

C25H35N7O6 (529.2649)

His Ile Asn Phe

C25H35N7O6 (529.2649)

His Lys Phe Val

C26H39N7O5 (529.3013)

His Lys Val Phe

C26H39N7O5 (529.3013)

His Leu Phe Asn

C25H35N7O6 (529.2649)

His Leu Asn Phe

C25H35N7O6 (529.2649)

His Asn Phe Ile

C25H35N7O6 (529.2649)

His Asn Phe Leu

C25H35N7O6 (529.2649)

His Asn Ile Phe

C25H35N7O6 (529.2649)

His Asn Leu Phe

C25H35N7O6 (529.2649)

His Gln Phe Val

C25H35N7O6 (529.2649)

His Gln Val Phe

C25H35N7O6 (529.2649)

His Arg Ala Phe

C24H35N9O5 (529.2761)

His Arg Phe Ala

C24H35N9O5 (529.2761)

His Val Phe Lys

C26H39N7O5 (529.3013)

His Val Phe Gln

C25H35N7O6 (529.2649)

His Val Lys Phe

C26H39N7O5 (529.3013)

His Val Gln Phe

C25H35N7O6 (529.2649)

Ile Glu Ile Arg

C23H43N7O7 (529.3224)

Ile Glu Leu Arg

C23H43N7O7 (529.3224)

Ile Glu Arg Ile

C23H43N7O7 (529.3224)

Ile Glu Arg Leu

C23H43N7O7 (529.3224)

Ile Phe His Asn

C25H35N7O6 (529.2649)

Ile Phe Asn His

C25H35N7O6 (529.2649)

Ile His Phe Asn

C25H35N7O6 (529.2649)

Ile His Asn Phe

C25H35N7O6 (529.2649)

Ile Ile Glu Arg

C23H43N7O7 (529.3224)

Ile Ile Arg Glu

C23H43N7O7 (529.3224)

Ile Ile Val Trp

C28H43N5O5 (529.3264)

Ile Ile Trp Val

C28H43N5O5 (529.3264)

Ile Lys Asn Arg

C22H43N9O6 (529.3336)

Ile Lys Arg Asn

C22H43N9O6 (529.3336)

Ile Leu Glu Arg

C23H43N7O7 (529.3224)

Ile Leu Arg Glu

C23H43N7O7 (529.3224)

Ile Leu Val Trp

C28H43N5O5 (529.3264)

Ile Leu Trp Val

C28H43N5O5 (529.3264)

Ile Asn Phe His

C25H35N7O6 (529.2649)

Ile Asn His Phe

C25H35N7O6 (529.2649)

Ile Asn Lys Arg

C22H43N9O6 (529.3336)

Ile Asn Gln Arg

C21H39N9O7 (529.2972)

Ile Asn Arg Lys

C22H43N9O6 (529.3336)

Ile Asn Arg Gln

C21H39N9O7 (529.2972)

Ile Gln Asn Arg

C21H39N9O7 (529.2972)

Ile Gln Arg Asn

C21H39N9O7 (529.2972)

Ile Arg Glu Ile

C23H43N7O7 (529.3224)

Ile Arg Glu Leu

C23H43N7O7 (529.3224)

Ile Arg Ile Glu

C23H43N7O7 (529.3224)

Ile Arg Lys Asn

C22H43N9O6 (529.3336)

Ile Arg Leu Glu

C23H43N7O7 (529.3224)

Ile Arg Asn Lys

C22H43N9O6 (529.3336)

Ile Arg Asn Gln

C21H39N9O7 (529.2972)

Ile Arg Gln Asn

C21H39N9O7 (529.2972)

Ile Val Ile Trp

C28H43N5O5 (529.3264)

Ile Val Leu Trp

C28H43N5O5 (529.3264)

Ile Val Trp Ile

C28H43N5O5 (529.3264)

Ile Val Trp Leu

C28H43N5O5 (529.3264)

Ile Trp Ile Val

C28H43N5O5 (529.3264)

Ile Trp Leu Val

C28H43N5O5 (529.3264)

Ile Trp Val Ile

C28H43N5O5 (529.3264)

Ile Trp Val Leu

C28H43N5O5 (529.3264)

Lys Phe His Val

C26H39N7O5 (529.3013)

Lys Phe Val His

C26H39N7O5 (529.3013)

Lys His Phe Val

C26H39N7O5 (529.3013)

Lys His Val Phe

C26H39N7O5 (529.3013)

Lys Ile Asn Arg

C22H43N9O6 (529.3336)

Lys Ile Arg Asn

C22H43N9O6 (529.3336)

Lys Leu Asn Arg

C22H43N9O6 (529.3336)

Lys Leu Arg Asn

C22H43N9O6 (529.3336)

Lys Asn Ile Arg

C22H43N9O6 (529.3336)

Lys Asn Leu Arg

C22H43N9O6 (529.3336)

Lys Asn Arg Ile

C22H43N9O6 (529.3336)

Lys Asn Arg Leu

C22H43N9O6 (529.3336)

Lys Gln Arg Val

C22H43N9O6 (529.3336)

Lys Gln Val Arg

C22H43N9O6 (529.3336)

Lys Arg Ile Asn

C22H43N9O6 (529.3336)

Lys Arg Leu Asn

C22H43N9O6 (529.3336)

Lys Arg Asn Ile

C22H43N9O6 (529.3336)

Lys Arg Asn Leu

C22H43N9O6 (529.3336)

Lys Arg Gln Val

C22H43N9O6 (529.3336)

Lys Arg Val Gln

C22H43N9O6 (529.3336)

Lys Val Phe His

C26H39N7O5 (529.3013)

Lys Val His Phe

C26H39N7O5 (529.3013)

Lys Val Gln Arg

C22H43N9O6 (529.3336)

Lys Val Arg Gln

C22H43N9O6 (529.3336)

Leu Glu Ile Arg

C23H43N7O7 (529.3224)

Leu Glu Leu Arg

C23H43N7O7 (529.3224)

Leu Glu Arg Ile

C23H43N7O7 (529.3224)

Leu Glu Arg Leu

C23H43N7O7 (529.3224)

Leu Phe His Asn

C25H35N7O6 (529.2649)

Leu Phe Asn His

C25H35N7O6 (529.2649)

Leu His Phe Asn

C25H35N7O6 (529.2649)

Leu His Asn Phe

C25H35N7O6 (529.2649)

Leu Ile Glu Arg

C23H43N7O7 (529.3224)

Leu Ile Arg Glu

C23H43N7O7 (529.3224)

Leu Ile Val Trp

C28H43N5O5 (529.3264)

Leu Ile Trp Val

C28H43N5O5 (529.3264)

Leu Lys Asn Arg

C22H43N9O6 (529.3336)

Leu Lys Arg Asn

C22H43N9O6 (529.3336)

Leu Leu Glu Arg

C23H43N7O7 (529.3224)

Leu Leu Arg Glu

C23H43N7O7 (529.3224)

Leu Leu Val Trp

C28H43N5O5 (529.3264)

Leu Leu Trp Val

C28H43N5O5 (529.3264)

Leu Asn Phe His

C25H35N7O6 (529.2649)

Leu Asn His Phe

C25H35N7O6 (529.2649)

Leu Asn Lys Arg

C22H43N9O6 (529.3336)

Leu Asn Gln Arg

C21H39N9O7 (529.2972)

Leu Asn Arg Lys

C22H43N9O6 (529.3336)

Leu Asn Arg Gln

C21H39N9O7 (529.2972)

Leu Gln Asn Arg

C21H39N9O7 (529.2972)

Leu Gln Arg Asn

C21H39N9O7 (529.2972)

Leu Arg Glu Ile

C23H43N7O7 (529.3224)

Leu Arg Glu Leu

C23H43N7O7 (529.3224)

Leu Arg Ile Glu

C23H43N7O7 (529.3224)

Leu Arg Lys Asn

C22H43N9O6 (529.3336)

Leu Arg Leu Glu

C23H43N7O7 (529.3224)

Leu Arg Asn Lys

C22H43N9O6 (529.3336)

Leu Arg Asn Gln

C21H39N9O7 (529.2972)

Leu Arg Gln Asn

C21H39N9O7 (529.2972)

Leu Val Ile Trp

C28H43N5O5 (529.3264)

Leu Val Leu Trp

C28H43N5O5 (529.3264)

Leu Val Trp Ile

C28H43N5O5 (529.3264)

Leu Val Trp Leu

C28H43N5O5 (529.3264)

Leu Trp Ile Val

C28H43N5O5 (529.3264)

Leu Trp Leu Val

C28H43N5O5 (529.3264)

Leu Trp Val Ile

C28H43N5O5 (529.3264)

Leu Trp Val Leu

C28H43N5O5 (529.3264)

Asn Phe His Ile

C25H35N7O6 (529.2649)

Asn Phe His Leu

C25H35N7O6 (529.2649)

Asn Phe Ile His

C25H35N7O6 (529.2649)

Asn Phe Leu His

C25H35N7O6 (529.2649)

Asn His Phe Ile

C25H35N7O6 (529.2649)

Asn His Phe Leu

C25H35N7O6 (529.2649)

Asn His Ile Phe

C25H35N7O6 (529.2649)

Asn His Leu Phe

C25H35N7O6 (529.2649)

Asn Ile Phe His

C25H35N7O6 (529.2649)

Asn Ile His Phe

C25H35N7O6 (529.2649)

Asn Ile Lys Arg

C22H43N9O6 (529.3336)

Asn Ile Gln Arg

C21H39N9O7 (529.2972)

Asn Ile Arg Lys

C22H43N9O6 (529.3336)

Asn Ile Arg Gln

C21H39N9O7 (529.2972)

Asn Lys Ile Arg

C22H43N9O6 (529.3336)

Asn Lys Leu Arg

C22H43N9O6 (529.3336)

Asn Lys Arg Ile

C22H43N9O6 (529.3336)

Asn Lys Arg Leu

C22H43N9O6 (529.3336)

Asn Leu Phe His

C25H35N7O6 (529.2649)

Asn Leu His Phe

C25H35N7O6 (529.2649)

Asn Leu Lys Arg

C22H43N9O6 (529.3336)

Asn Leu Gln Arg

C21H39N9O7 (529.2972)

Asn Leu Arg Lys

C22H43N9O6 (529.3336)

Asn Leu Arg Gln

C21H39N9O7 (529.2972)

Asn Gln Ile Arg

C21H39N9O7 (529.2972)

Asn Gln Leu Arg

C21H39N9O7 (529.2972)

Asn Gln Arg Ile

C21H39N9O7 (529.2972)

Asn Gln Arg Leu

C21H39N9O7 (529.2972)

Asn Arg Ile Lys

C22H43N9O6 (529.3336)

Asn Arg Ile Gln

C21H39N9O7 (529.2972)

Asn Arg Lys Ile

C22H43N9O6 (529.3336)

Asn Arg Lys Leu

C22H43N9O6 (529.3336)

Asn Arg Leu Lys

C22H43N9O6 (529.3336)

Asn Arg Leu Gln

C21H39N9O7 (529.2972)

Asn Arg Gln Ile

C21H39N9O7 (529.2972)

Asn Arg Gln Leu

C21H39N9O7 (529.2972)

Gln Ala Arg Arg

C20H39N11O6 (529.3085)

Gln Phe His Val

C25H35N7O6 (529.2649)

Gln Phe Val His

C25H35N7O6 (529.2649)

Gln His Phe Val

C25H35N7O6 (529.2649)

Gln His Val Phe

C25H35N7O6 (529.2649)

Gln Ile Asn Arg

C21H39N9O7 (529.2972)

Gln Ile Arg Asn

C21H39N9O7 (529.2972)

Gln Lys Arg Val

C22H43N9O6 (529.3336)

Gln Lys Val Arg

C22H43N9O6 (529.3336)

Gln Leu Asn Arg

C21H39N9O7 (529.2972)

Gln Leu Arg Asn

C21H39N9O7 (529.2972)

Gln Asn Ile Arg

C21H39N9O7 (529.2972)

Gln Asn Leu Arg

C21H39N9O7 (529.2972)

Gln Asn Arg Ile

C21H39N9O7 (529.2972)

Gln Asn Arg Leu

C21H39N9O7 (529.2972)

Gln Gln Arg Val

C21H39N9O7 (529.2972)

Gln Gln Val Arg

C21H39N9O7 (529.2972)

Gln Arg Ala Arg

C20H39N11O6 (529.3085)

Gln Arg Ile Asn

C21H39N9O7 (529.2972)

Gln Arg Lys Val

C22H43N9O6 (529.3336)

Gln Arg Leu Asn

C21H39N9O7 (529.2972)

Gln Arg Asn Ile

C21H39N9O7 (529.2972)

Gln Arg Asn Leu

C21H39N9O7 (529.2972)

Gln Arg Gln Val

C21H39N9O7 (529.2972)

Gln Arg Arg Ala

C20H39N11O6 (529.3085)

Gln Arg Val Lys

C22H43N9O6 (529.3336)

Gln Arg Val Gln

C21H39N9O7 (529.2972)

Gln Val Phe His

C25H35N7O6 (529.2649)

Gln Val His Phe

C25H35N7O6 (529.2649)

Gln Val Lys Arg

C22H43N9O6 (529.3336)

Gln Val Gln Arg

C21H39N9O7 (529.2972)

Gln Val Arg Lys

C22H43N9O6 (529.3336)

Gln Val Arg Gln

C21H39N9O7 (529.2972)

Arg Ala Phe His

C24H35N9O5 (529.2761)

Arg Ala His Phe

C24H35N9O5 (529.2761)

Arg Ala Gln Arg

C20H39N11O6 (529.3085)

Arg Ala Arg Gln

C20H39N11O6 (529.3085)

Arg Glu Ile Ile

C23H43N7O7 (529.3224)

Arg Glu Ile Leu

C23H43N7O7 (529.3224)

Arg Glu Leu Ile

C23H43N7O7 (529.3224)

Arg Glu Leu Leu

C23H43N7O7 (529.3224)

Arg Phe Ala His

C24H35N9O5 (529.2761)

Arg Phe His Ala

C24H35N9O5 (529.2761)

Arg His Ala Phe

C24H35N9O5 (529.2761)

Arg His Phe Ala

C24H35N9O5 (529.2761)

Arg Ile Glu Ile

C23H43N7O7 (529.3224)

Arg Ile Glu Leu

C23H43N7O7 (529.3224)

Arg Ile Ile Glu

C23H43N7O7 (529.3224)

Arg Ile Lys Asn

C22H43N9O6 (529.3336)

Arg Ile Leu Glu

C23H43N7O7 (529.3224)

Arg Ile Asn Lys

C22H43N9O6 (529.3336)

Arg Ile Asn Gln

C21H39N9O7 (529.2972)

Arg Ile Gln Asn

C21H39N9O7 (529.2972)

Arg Lys Ile Asn

C22H43N9O6 (529.3336)

Arg Lys Leu Asn

C22H43N9O6 (529.3336)

Arg Lys Asn Ile

C22H43N9O6 (529.3336)

Arg Lys Asn Leu

C22H43N9O6 (529.3336)

Arg Lys Gln Val

C22H43N9O6 (529.3336)

Arg Lys Val Gln

C22H43N9O6 (529.3336)

Arg Leu Glu Ile

C23H43N7O7 (529.3224)

Arg Leu Glu Leu

C23H43N7O7 (529.3224)

Arg Leu Ile Glu

C23H43N7O7 (529.3224)

Arg Leu Lys Asn

C22H43N9O6 (529.3336)

Arg Leu Leu Glu

C23H43N7O7 (529.3224)

Arg Leu Asn Lys

C22H43N9O6 (529.3336)

Arg Leu Asn Gln

C21H39N9O7 (529.2972)

Arg Leu Gln Asn

C21H39N9O7 (529.2972)

Arg Asn Ile Lys

C22H43N9O6 (529.3336)

Arg Asn Ile Gln

C21H39N9O7 (529.2972)

Arg Asn Lys Ile

C22H43N9O6 (529.3336)

Arg Asn Lys Leu

C22H43N9O6 (529.3336)

Arg Asn Leu Lys

C22H43N9O6 (529.3336)

Arg Asn Leu Gln

C21H39N9O7 (529.2972)

Arg Asn Gln Ile

C21H39N9O7 (529.2972)

Arg Asn Gln Leu

C21H39N9O7 (529.2972)

Arg Gln Ala Arg

C20H39N11O6 (529.3085)

Arg Gln Ile Asn

C21H39N9O7 (529.2972)

Arg Gln Lys Val

C22H43N9O6 (529.3336)

Arg Gln Leu Asn

C21H39N9O7 (529.2972)

Arg Gln Asn Ile

C21H39N9O7 (529.2972)

Arg Gln Asn Leu

C21H39N9O7 (529.2972)

Arg Gln Gln Val

C21H39N9O7 (529.2972)

Arg Gln Arg Ala

C20H39N11O6 (529.3085)

Arg Gln Val Lys

C22H43N9O6 (529.3336)

Arg Gln Val Gln

C21H39N9O7 (529.2972)

Arg Arg Ala Gln

C20H39N11O6 (529.3085)

Arg Arg Gln Ala

C20H39N11O6 (529.3085)

Arg Val Lys Gln

C22H43N9O6 (529.3336)

Arg Val Gln Lys

C22H43N9O6 (529.3336)

Arg Val Gln Gln

C21H39N9O7 (529.2972)

Val Phe His Lys

C26H39N7O5 (529.3013)

Val Phe His Gln

C25H35N7O6 (529.2649)

Val Phe Lys His

C26H39N7O5 (529.3013)

Val Phe Gln His

C25H35N7O6 (529.2649)

Val His Phe Lys

C26H39N7O5 (529.3013)

Val His Phe Gln

C25H35N7O6 (529.2649)

Val His Lys Phe

C26H39N7O5 (529.3013)

Val His Gln Phe

C25H35N7O6 (529.2649)

Val Ile Ile Trp

C28H43N5O5 (529.3264)

Val Ile Leu Trp

C28H43N5O5 (529.3264)

Val Ile Trp Ile

C28H43N5O5 (529.3264)

Val Ile Trp Leu

C28H43N5O5 (529.3264)

Val Lys Phe His

C26H39N7O5 (529.3013)

Val Lys His Phe

C26H39N7O5 (529.3013)

Val Lys Gln Arg

C22H43N9O6 (529.3336)

Val Lys Arg Gln

C22H43N9O6 (529.3336)

Val Leu Ile Trp

C28H43N5O5 (529.3264)

Val Leu Leu Trp

C28H43N5O5 (529.3264)

Val Leu Trp Ile

C28H43N5O5 (529.3264)

Val Leu Trp Leu

C28H43N5O5 (529.3264)

Val Gln Phe His

C25H35N7O6 (529.2649)

Val Gln His Phe

C25H35N7O6 (529.2649)

Val Gln Lys Arg

C22H43N9O6 (529.3336)

Val Gln Gln Arg

C21H39N9O7 (529.2972)

Val Gln Arg Lys

C22H43N9O6 (529.3336)

Val Gln Arg Gln

C21H39N9O7 (529.2972)

Val Arg Lys Gln

C22H43N9O6 (529.3336)

Val Arg Gln Lys

C22H43N9O6 (529.3336)

Val Arg Gln Gln

C21H39N9O7 (529.2972)

Val Trp Ile Ile

C28H43N5O5 (529.3264)

Val Trp Ile Leu

C28H43N5O5 (529.3264)

Val Trp Leu Ile

C28H43N5O5 (529.3264)

Val Trp Leu Leu

C28H43N5O5 (529.3264)

Trp Ile Ile Val

C28H43N5O5 (529.3264)

Trp Ile Leu Val

C28H43N5O5 (529.3264)

Trp Ile Val Ile

C28H43N5O5 (529.3264)

Trp Ile Val Leu

C28H43N5O5 (529.3264)

Trp Leu Ile Val

C28H43N5O5 (529.3264)

Trp Leu Leu Val

C28H43N5O5 (529.3264)

Trp Leu Val Ile

C28H43N5O5 (529.3264)

Trp Leu Val Leu

C28H43N5O5 (529.3264)

Trp Val Ile Ile

C28H43N5O5 (529.3264)

Trp Val Ile Leu

C28H43N5O5 (529.3264)

Trp Val Leu Ile

C28H43N5O5 (529.3264)

Trp Val Leu Leu

C28H43N5O5 (529.3264)

AKGRV

C22H43N9O6 (529.3336)

N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfoxy)cholan-24-yl]-Glycine

C26H43NO8S (529.2709)

LPE(22:4)

C27H48NO7P (529.3168)

N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]-Glycine

C26H43NO8S (529.2709)

Glycine, N-[(3a,5b,7b)-3-hydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]

C26H43NO8S (529.2709)

Glycine, N-[(3a,5b,7a)-3-hydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-

C26H43NO8S (529.2709)

Glycochenodeoxycholate-3-sulfate

C26H43NO8S (529.2709)

LysoPE(22:4/0:0)

C27H48NO7P (529.3168)

LPE 22:4

C27H48NO7P (529.3168)

Glycochenodeoxycholate 7-sulfate

C26H43NO8S (529.2709)

N-methyltaurocholic acid

C27H47NO7S (529.3073)

3-Hydroxymethyl Maraviroc

C29H41F2N5O2 (529.3228)

4-Hydroxyphenyl Maraviroc

C29H41F2N5O2 (529.3228)

Galanthamine derivative

C32H37N2O5+ (529.2702)

Haloperidol decanoate

C31H41ClFNO3 (529.2759)

D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist

Glycodeoxycholic acid sulfate

C26H43NO8S (529.2709)

N(6)-acetylkanamycin B(4+)

C20H43N5O11+4 (529.2959)

(E)-4-[[3-(acetylhydroxyamino)propyl]-amino]-2-hydroxy-2-[2-[3-[hydroxy(1-oxo-2-decenyl)amino]propyl]amino]-2-oxoethyl]-4-oxobutanoic acid

C24H41N4O9- (529.2873)

(5Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine

C30H43NO7 (529.3039)

1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea

C32H39N3O4 (529.294)

1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea

C32H39N3O4 (529.294)

2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C31H35N3O5 (529.2577)

1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea

C32H39N3O4 (529.294)

1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea

C32H39N3O4 (529.294)

1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea

C32H39N3O4 (529.294)

2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C31H35N3O5 (529.2577)

2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C31H35N3O5 (529.2577)

1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea

C32H39N3O4 (529.294)

1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea

C32H39N3O4 (529.294)

2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C31H35N3O5 (529.2577)

1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea

C32H39N3O4 (529.294)

1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea

C32H39N3O4 (529.294)

1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea

C32H39N3O4 (529.294)

1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea

C32H39N3O4 (529.294)

1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea

C32H39N3O4 (529.294)

2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C31H35N3O5 (529.2577)

2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C31H35N3O5 (529.2577)

2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C31H35N3O5 (529.2577)

2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C31H35N3O5 (529.2577)

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C27H48NO7P (529.3168)

Lnape 3:0/N-18:4

C26H44NO8P (529.2804)

Lnape 18:4/N-3:0

C26H44NO8P (529.2804)

[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-2-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C27H48NO7P (529.3168)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] hexanoate

C27H48NO7P (529.3168)

[3-acetyloxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H44NO8P (529.2804)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] butanoate

C27H48NO7P (529.3168)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] acetate

C27H48NO7P (529.3168)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C26H44NO8P (529.2804)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C26H44NO8P (529.2804)

lysoPE 22:4

C27H48NO7P (529.3168)

sulfoglycochenodeoxycholic acid

C26H43NO8S (529.2709)

A steroid sulfate that is the 3-O-sulfo derivative of glycochenodeoxycholic acid.

LysoPE(0:0/22:4(7Z,10Z,13Z,16Z))

C27H48NO7P (529.3168)

LPE(22:4(7Z,10Z,13Z,16Z)/0:0)

C27H48NO7P (529.3168)

PE(22:4/0:0)

C27H48NO7P (529.3168)

A lysophosphatidylethanolamine 22:4 in which the acyl group is located at position 1.

N(6)-acetylkanamycin B(4+)

C20H43N5O11 (529.2959)

A quadruply-charged ammonium ion arising from protonation of the four free amino groups of N(6)-acetylkanamycin; major species at pH 7.3.

PE(22:4)

C27H48NO7P (529.3168)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

PC(18:4)

C26H44NO8P (529.2804)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

PE(21:4)

C26H44NO8P (529.2804)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

LdMePE(20:4)

C27H48NO7P (529.3168)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

MePC(18:4)

C27H48NO7P (529.3168)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

MePC(17:4)

C26H44NO8P (529.2804)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

PC(19:4)

C27H48NO7P (529.3168)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

PC O-16:4/3:0

C27H48NO7P (529.3168)

LNAPE 21:4

C26H44NO8P (529.2804)

LPE 0:0/22:4

C27H48NO7P (529.3168)

LPE 22:4/0:0

C27H48NO7P (529.3168)

PE O-22:4

C27H48NO7P (529.3168)

PE P-18:1/4:2

C27H48NO7P (529.3168)

PE P-22:3

C27H48NO7P (529.3168)

PE P-22:3 or PE O-22:4

C27H48NO7P (529.3168)

PE 21:4

C26H44NO8P (529.2804)

Glycodeoxycholate sulfate

C26H43NO8S (529.2709)

Glycodeoxycholic acid 3-sulfate

C26H43NO8S (529.2709)

ST 25:0;O7;Gly

C27H47NO9 (529.3251)

ST 27:6;O6;Gly

C29H39NO8 (529.2676)

ST 28:5;O5;Gly

C30H43NO7 (529.3039)

ST 18:0;O5;HexNAc

C26H43NO10 (529.2887)

ST 21:5;O3;HexNAc

C29H39NO8 (529.2676)

ST 22:4;O2;HexNAc

C30H43NO7 (529.3039)

ST 24:2;O5;Tau

C26H43NO8S (529.2709)

ST 25:1;O4;Tau

C27H47NO7S (529.3073)

ST 28:6;O2;Tau

C30H43NO5S (529.2862)

Glycochenodeoxycholic acid 3-sulfate

C26H43NO8S (529.2709)

-

(2s,3s,6r)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl (3r)-3-hydroxy-3-(4-methylpentyl)butanedioate

C29H39NO8 (529.2676)

(2r,3s,6s)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl (3s)-3-hydroxy-3-(4-methylpentyl)butanedioate

C29H39NO8 (529.2676)

2-{4,6'-dihydroxy-2',5',5',8'a-tetramethyl-6-oxo-3,3',4',4'a,6',7',8,8'-octahydro-2'h-spiro[furo[2,3-e]isoindole-2,1'-naphthalen]-7-yl}-5-methoxy-5-oxopentanoic acid

C29H39NO8 (529.2676)

2-{n-[1-(4-decyl-3-hydroxy-2-oxo-5h-pyrrol-1-yl)-3-methyl-1-oxobutan-2-yl]-(c-hydroxycarbonimidoyl)amino}-3-phenylpropanoic acid

C29H43N3O6 (529.3152)

6-{3,6,9,13-tetrahydroxy-8-[(4-hydroxyphenyl)methyl]-2-isopropyl-5,12-dimethyl-1,4,7,10-tetraazacyclotrideca-1(13),3,6,9-tetraen-11-yl}hex-4-enimidic acid

C27H39N5O6 (529.29)

(1s,3r,4s,5s,8s,9r,10s,11r,14r,16s,17s,18s,19r)-4,9-bis(acetyloxy)-10,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl (2s)-2-methylbutanoate

C29H39NO8 (529.2676)

(1s,3r,4s,5s,8s,9r,11r,14r,16s,17s,18s,19s)-4,9-bis(acetyloxy)-10,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl 2-methylbutanoate

C29H39NO8 (529.2676)

1-[11-(acetyloxy)-1,3a,3b,7-tetrahydroxy-9a,11a-dimethyl-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl pyridine-3-carboxylate

C29H39NO8 (529.2676)

4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl 3-hydroxy-3-(4-methylpentyl)butanedioate

C29H39NO8 (529.2676)

(1s,3r,4s,5s,8s,9r,10s,11r,14r,16s,17s,18s,19r)-4,10-bis(acetyloxy)-9,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl (2s)-2-methylbutanoate

C29H39NO8 (529.2676)

(1s,3r,4s,5r,8s,9r,10r,11r,14r,16s,17s,18s,19s)-4,9-bis(acetyloxy)-10,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl (2r)-2-methylbutanoate

C29H39NO8 (529.2676)

(2s)-2-[(2r,2'r,4'as,6'r,8'as)-4,6'-dihydroxy-2',5',5',8'a-tetramethyl-6-oxo-3,3',4',4'a,6',7',8,8'-octahydro-2'h-spiro[furo[2,3-e]isoindole-2,1'-naphthalen]-7-yl]-5-methoxy-5-oxopentanoic acid

C29H39NO8 (529.2676)

(4z)-6-[(2r,5r,8r,11r,12s)-3,6,9,13-tetrahydroxy-8-[(4-hydroxyphenyl)methyl]-2-isopropyl-5,12-dimethyl-1,4,7,10-tetraazacyclotrideca-1(13),3,6,9-tetraen-11-yl]hex-4-enimidic acid

C27H39N5O6 (529.29)

(4s)-4-[(2r,2'r,4'as,6'r,8'as)-4,6'-dihydroxy-2',5',5',8'a-tetramethyl-6-oxo-3,3',4',4'a,6',7',8,8'-octahydro-2'h-spiro[furo[2,3-e]isoindole-2,1'-naphthalen]-7-yl]-5-methoxy-5-oxopentanoic acid

C29H39NO8 (529.2676)

(1s)-1-[(1s,3ar,3bs,7s,9ar,9br,11r,11ar)-11-(acetyloxy)-1,3a,3b,7-tetrahydroxy-9a,11a-dimethyl-2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl pyridine-3-carboxylate

C29H39NO8 (529.2676)

1-[(6s)-2,3-dihydroxy-7,8-dimethoxy-5-methyl-1,4-bis(2-methylbut-3-en-2-yl)-6h-benzo[c]phenanthridin-6-yl]propan-2-one

C33H39NO5 (529.2828)

(1s,3r,4s,5s,8s,9r,11r,14r,16s,17s,18s,19s)-4,10-bis(acetyloxy)-9,19-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl 2-methylbutanoate

C29H39NO8 (529.2676)

4-{4,6'-dihydroxy-2',5',5',8'a-tetramethyl-6-oxo-3,3',4',4'a,6',7',8,8'-octahydro-2'h-spiro[furo[2,3-e]isoindole-2,1'-naphthalen]-7-yl}-5-methoxy-5-oxopentanoic acid

C29H39NO8 (529.2676)